Isentress 400mg Tablet (Raltegravir)

Isentress 400mg Tablet is an antiretrovirals medicine contains Raltegravir (400mg) as an active ingredient. It is prescribed to treat HIV (human immunodeficiency virus) infection. Isentress prevent the multiplication of HIV and reduce the viral load in the body. It also increases the CD4 cell count in the blood. Moreover, this tablet boosts immune functioning to fight against HIV infection and manage or treat AIDS. Always take it under medical supervision.

HIV infection

Isentress 400mg Tablet(Raltegravir 400mg) is a strong anti-HIV medicine that may show certain adverse while manageable impact on the body during the treatment. As these effects resolve on their own without any special medical attention. However, if you ever experience serious or unusual side effects contact your healthcare professional immediately.
Some common side effects include:
● Insomnia (difficulty sleeping)
● Diarrhea
● Dizziness
● Fatigue
● Headache
● Nausea
● Abdominal pain
● Abnormal dreams
● Decreased appetite
● Depression
● Flatulence
● Nightmares
● Vomiting
● Weakness

Doctor determines the dosage and duration of Isentress 400mg Tablet(Raltegravir 400mg) as per the severity of infection as well as age & overall health condition of the patients. Swallow it as a whole with water and don't chew, crush or break the tablet. This tablet may be taken with or without food. In case of an overdose of this tablet, contact your doctor or any healthcare provider and seek medical attention immediately.

● Temesgen, Z., & Siraj, D. S. (2008). Raltegravir: first in class HIV integrase inhibitor. Therapeutics and clinical risk management, 4(2), 493-500.
● Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., ... & Nguyen, B. Y. (2008). Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. New England Journal of Medicine, 359(4), 355-365.
● Elzi, L., Erb, S., Furrer, H., Cavassini, M., Calmy, A., Vernazza, P., ... & Swiss HIV Cohort Study Group. (2017). Adverse events of raltegravir and dolutegravir. Aids, 31(13), 1853-1858.
● Grinsztejn, B., Nguyen, B. Y., Katlama, C., Gatell, J. M., Lazzarin, A., Vittecoq, D., ... & Isaacs, R. D. (2007). Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. The Lancet, 369(9569), 1261-1269.
● J Buzón, M., Massanella, M., Llibre, J. M., Esteve, A., Dahl, V., Puertas, M. C., ... & Martinez-Picado, J. (2010). HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature medicine, 16(4), 460-465.